PRETREATMENT SOLUBLE INTERLEUKIN‐2 RECEPTOR LEVEL WAS A ROBUST PROGNOSTIC FACTOR IN FOLLICULAR LYMPHOMA IN RITUXIMAB ERA. (June 2017)